Commercial plans and market opportunity for their recently approved drug (GOCOVRI™) for the treatment
of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, and an overview of the pipeline products.
Date: September 18, 2017
Time: 8:00AM - 11:00AM
Rajesh Pahwa, MD, Laverne & Joyce Rider
Professor of Neurology at the Kansas Medical Center and Director,
Parkinson's Disease Center of Excellence at the University of Kansas Health System
For more information or to RSVP, please contact Marcy Nanus (email@example.com)